Literature DB >> 29693280

Case of complete response to neoadjuvant therapy using nivolumab in a patient with metastatic renal cell carcinoma.

Daiki Ikarashi1, Yoichiro Kato1, Hirokatsu Katagiri2, Takeshi Takahara2, Noriyuki Uesugi3, Ei Shiomi1, Jun Sugimura1, Hiroyuki Nitta2, Tamotsu Sugai3, Wataru Obara1.   

Abstract

Here, we report a case of a 68-year-old woman with cT4N0M1 (liver invasion and multiple lung metastases) metastatic renal cell carcinoma. We could carry out less invasive nephrectomy with partial hepatectomy because nivolumab administration as second-line therapy reduced the primary tumor remarkably. To the best of our knowledge, this is the first report of the use of nivolumab before carrying out surgery, and histological findings showed a pathological complete response.
© 2018 The Japanese Urological Association.

Entities:  

Keywords:  liver invasion; neoadjuvant; nephrectomy; nivolumab; renal cell carcinoma

Mesh：

Substances：

Year:  2018        PMID： 29693280     DOI： 10.1111/iju.13590

Source DB:  PubMed          Journal:  Int J Urol        ISSN： 0919-8172            Impact factor:   3.369


  9 in total

Review 1.  Overview on the role of preoperative therapy in the management of kidney cancer.

Authors:  T Assi; E El Rassy; F Farhat; J Kattan
Journal:  Clin Transl Oncol       Date:  2019-05-29       Impact factor: 3.405

2.  Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database.

Authors:  Nirmish Singla; Ryan C Hutchinson; Rashed A Ghandour; Yuval Freifeld; Dong Fang; Arthur I Sagalowsky; Yair Lotan; Aditya Bagrodia; Vitaly Margulis; Hans J Hammers; Solomon L Woldu
Journal:  Urol Oncol       Date:  2020-04-03       Impact factor: 3.498

3.  Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma.

Authors:  Hiroki Hagimoto; Soki Kashima; Kazuki Doi; Shintaro Nakayama; Takanori Sano; Satoshi Imai; Tomihiko Yasufuku; Mototsugu Muramaki; Yuji Yamada
Journal:  IJU Case Rep       Date:  2020-10-05

4.  Rapid progression of recurrent disease in a patient with renal cell carcinoma with vaginal metastasis.

Authors:  Mizuki Hisano; Renpei Kato; Hiroaki Itamochi; Tomohiko Matsuura; Shigekatsu Maekawa; Yoichiro Kato; Mitsugu Kanehira; Ryo Takata; Tsukasa Baba; Wataru Obara
Journal:  IJU Case Rep       Date:  2020-07-07

5.  Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma.

Authors:  Emilien Billon; Jochen Walz; Serge Brunelle; Jeanne Thomassin; Naji Salem; Mathilde Guerin; Cecile Vicier; Slimane Dermeche; Laurence Albiges; Florence Tantot; Soazig Nenan; Geraldine Pignot; Gwenaëlle Gravis
Journal:  Front Oncol       Date:  2019-10-09       Impact factor: 6.244

Review 6.  Cytoreductive Nephrectomy Following Immunotherapy-Base Treatment in Metastatic Renal Cell Carcinoma: A Case Series and Review of Current Literature.

Authors:  Scott J Dawsey; Steven C Campbell; Moshe C Ornstein
Journal:  Curr Oncol       Date:  2021-05-20       Impact factor: 3.677

7.  Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma.

Authors:  Nirmish Singla; Roy Elias; Rashed A Ghandour; Yuval Freifeld; Isaac A Bowman; Leonid Rapoport; Mikhail Enikeev; Jay Lohrey; Solomon L Woldu; Jeffrey C Gahan; Aditya Bagrodia; James Brugarolas; Hans J Hammers; Vitaly Margulis
Journal:  Urol Oncol       Date:  2019-09-12       Impact factor: 2.954

8.  A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma.

Authors:  Hana Studentova; Anezka Zemankova; Martina Spisarova; Daniela Skanderova; Zbynek Tudos; Bohuslav Melichar; Vladimir Student
Journal:  Medicina (Kaunas)       Date:  2022-02-23       Impact factor: 2.430

9.  Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b).

Authors:  Marco Stellato; Daniele Santini; Elena Verzoni; Ugo De Giorgi; Francesco Pantano; Chiara Casadei; Giuseppe Fornarini; Marco Maruzzo; Andrea Sbrana; Giuseppe Di Lorenzo; Mariella Soraru; Emanuele Naglieri; Sebastiano Buti; Rocco De Vivo; Andrea Napolitano; Francesca Vignani; Claudia Mucciarini; Francesco Grillone; Giandomenico Roviello; Marilena Di Napoli; Giuseppe Procopio
Journal:  Front Oncol       Date:  2021-06-08       Impact factor: 6.244
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.